February 15, 2021 • 10:17 am CST
(Precision Vaccinations)
The Karaganda Pharmaceutical Complex, located in Karaganda, Kazakhstan, announced on February 15, 2021, plans to leverage the Sputnik V vaccine to produce the QazCovid-In Vaccine, reported TASS.
This COVID-19 vaccine candidate is currently undergoing a phase 3 clinical study sponsored by Research Institute for Biological Safety Problems. This study's estimated Primary Completion Date is March 31, 2021.
On February 1st, Kazakhstan began its coronavirus vaccination campaign by administering the Sputnik V vaccine, which is authorized in about 26 countries.
The COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.